Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roila, F.
Right arrow Articles by Cortesi, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roila, F.
Right arrow Articles by Cortesi, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S3-S6, 2001
© 2001 European Society for Medical Oncology

Symposium Article

Quality of life as a primary end point in oncology

Fausto Roila1 and Enrico Cortesi2

1 Medical Oncology Division, Polichnico Hospital Perugia
2 Department of Experimental Medicine, ‘La Sapienza’ University Rome, Italy

Correspondence to: F. Roila, MD Medical Oncology Division Policlinico Hospital 06122 Perugia Italy E-mail: roila.fausto{at}edisons.it

Background: In cancer clinical trials, the standard end points include response rates, progression free and overall survival, toxicity. These evaluation criteria do not measure how the cancer and its treatment affect the quality of life of cancer patients.

Design: The relevant literature was reviewed for the purposes of determining when, how and why quality of life should be measured in cancer clinical trials. The resulting clinical benefits were also reviewed.

Results: Along with survival, quality of life is the main end point of comparative clinical trials. Its evaluation can provide physicians and patients with important information and help to identify a better treatment. Cancer-specific questionnaires with forms for specific tumour types sites have been developed and have proven to be more sensitive to changes than generic questionnaires. Quality-of-life evaluation before the start of treatment may be an important prognostic factor, even independent from performance status. Clinical benefit assessment presents important shortcomings and the clinical relevance of this evaluation should be interpreted with caution.

Conclusions: Quality of life is a fundamental task of oncological research. More studies are necessary to overcome the difficulties in assessing and interpreting this concept and the clinical benefits based on it.

clinical benefit, quality of life, research end point


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.